EUVIMEDObjevte EUVIMED
Open access

Children's Oncology Group's 2023 blueprint for research: Bone tumors

Damon R Reed, Patrick Grohar, Elyssa Rubin, Odion Binitie, Mark Krailo, Jessica Davis iD, Steven G DuBois iD, Katherine A Janeway iD

Pediatric Blood & Cancer · 2023

DOI: 10.1002/pbc.30583 ↗

At a glance

Journal article in Pediatric Blood & Cancer, 2023. Written by Damon R Reed and 7 co-authors. Institution: Department of Individualized Cancer Management, Moffitt Cancer Center, Tampa, Florida, USA. Major MEDLINE topics: Bone Neoplasms, Sarcoma, Ewing, Osteosarcoma, Neuroectodermal Tumors, Primitive, Peripheral. Cited 19 times so far (Crossref); 73 references. The full text is freely available in PubMed Central. Funded by: NCI NIH HHS, NIH HHS, National Institutes of Health.

AbstraktSubjectsBibliografické údajeCiteRelated studies

Abstract (original language)

The Children's Oncology Group (COG) Bone Tumor Committee is responsible for clinical trials and biological research on localized, metastatic, and recurrent osteosarcoma and Ewing sarcoma (EWS). Results of clinical trials in localized disease completed and published in the past 10 years have led to international standard‐of‐care chemotherapy for osteosarcoma and EWS. A recent focus on identifying disease subgroups has led to the identification of biological features associated with poor outcomes including the presence of circulating tumor DNA (ctDNA) at diagnosis, and specific genomic alterations—MYC amplification for osteosarcoma and STAG2 and TP53 mutation for EWS. Studies validating these potential biomarkers are under way. Clinical trials evaluating the addition of multitargeted kinase inhibitors, which are active in relapsed bone sarcomas, to standard chemotherapy are under way in osteosarcoma and planned in EWS. In addition, the Committee has data analyses and a clinical trial under way to evaluate approaches to local management of the primary tumor and metastatic sites. Given the rarity of bone sarcomas, we have prioritized international interactions and are in the process of forming an international data‐sharing consortium to facilitate refinement of risk stratification and study of rare disease subtypes.

Subjects

MeSH terms (MEDLINE)

Bone NeoplasmsSarcoma, EwingOsteosarcomaNeuroectodermal Tumors, Primitive, PeripheralChildHumansNeoplasm Recurrence, Local

Author keywords

Bone sarcomaEwing sarcomaosteosarcomaresearch priorities

Authors and institutions

  • Department of Individualized Cancer Management, Moffitt Cancer Center, Tampa, Florida, USA.
  • Division of Oncology, Children's Hospital of Philadelphia Research Institute, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
  • Department of Oncology, Children's Hospital of Orange County, Orange, California, USA.
  • Department of Sarcoma, Moffitt Cancer Center, Tampa, Florida, USA.
  • Keck School of Medicine, University of Southern California and Children's Oncology Group, Monrovia, California, USA.
  • Department of Pathology and Laboratory Medicine, Indiana University School of Medicine, Indianapolis, Indiana, USA.

ORCID profiles: Jessica Davis, Steven G DuBois, Katherine A Janeway

Funding

  • NCI NIH HHS
  • NIH HHS
  • National Institutes of Health

Cite

APA

Reed, D. R., Grohar, P., Rubin, E., Binitie, O., Krailo, M., Davis, J., DuBois, S. G., & Janeway, K. A. (2023). Children's Oncology Group's 2023 blueprint for research: Bone tumors. Pediatric Blood & Cancer. https://doi.org/10.1002/pbc.30583

Vancouver

Reed DR, Grohar P, Rubin E, Binitie O, Krailo M, Davis J, et al. Children's Oncology Group's 2023 blueprint for research: Bone tumors. Pediatric Blood & Cancer. 2023. doi:10.1002/pbc.30583

BibTeX
@article{Reed2023,
  author = {Reed, Damon R and Grohar, Patrick and Rubin, Elyssa and Binitie, Odion and Krailo, Mark and Davis, Jessica and DuBois, Steven G and Janeway, Katherine A},
  title = {Children's Oncology Group's 2023 blueprint for research: Bone tumors},
  journal = {Pediatric Blood & Cancer},
  year = {2023},
  doi = {10.1002/pbc.30583}
}
Start for free →